INTRODUCTION
Enterococci are facultative anaerobic bacteria tolerant of a wide range of environmental conditions and constitute normal commensal flora of the human gastrointestinal tract. Some species of this genus have a high intrinsic resistance to antibiotics [1, 2] . In addition, over the last two decades, particularly virulent strains of enterococci with acquired resistance to antibiotics, such as vancomycin, have emerged.
Thus, associated treatment and infection control have become increasingly difficult [3] . The constitutive presence of enterococci in gastrointestinal tracts of hospitalized patients has assisted the transition from commensal organisms to nosocomial pathogens and the evolution of such drug resistance [4, 5] .
Moreover, establishment of such multidrugresistant pathogens is particularly common and therapeutically problematic in the hospital setting [6, 7] , and thus constitutes a significant and growing public health challenge [8, 9] .
Enterococci are often encountered in mixed infections and are particularly found in urinary tract infections, bacteremia, endocarditis, diverticulitis, peritonitis, and meningitis [3] . In recent years, the prevalence of species other than Enterococcus faecalis has increased.
Particular
Enterococcus faecium strains frequently showing multidrug resistance and non-susceptibility to vancomycin have emerged. Few therapeutic options are available for treating infections caused by vancomycinresistant enterococci (VRE) [6] .
Daptomycin is a cyclic lipopeptide with rapid bactericidal activity against a wide range of Gram-positive bacteria, including multidrugresistant enterococci [10] [11] [12] [13] [14] , and is effective in inhibiting or disrupting biofilm production in vitro [15] [16] [17] . Its mechanism of action is distinct from that of other antibiotics, including b-lactams, aminoglycosides, glycopeptides, fluoroquinolones, and macrolides. In the presence of physiological concentrations of ionized calcium, daptomycin interacts with the surface of Gram-positive bacteria, leading to disruption of membrane function [18] .
Daptomycin was first approved in 2003, and is indicated for the treatment of complicated skin and soft tissue infections (cSSTIs; 4 mg/kg every 24 h), right-sided endocarditis due to Staphylococcus aureus and for bacteremia associated with cSSTI or right-sided endocarditis (6 mg/kg every 24 h) [19] . It has been previously shown that daptomycin (6 mg/kg/day) was highly effective against susceptible and multidrug-resistant E. faecalis and E. faecium in vitro and also in a rat model of experimental endocarditis [20] . Moreover, treatment with daptomycin in patients with invasive or bacteremic enterococcal infections leads to higher frequency of cure (up to 90% or more) when concomitant and adequate focus relief was performed [21] . [24] .
Clinical success was used to collectively describe patients with an outcome of cured or improved. Time to improvement was also recorded. Duration of treatment was measured as the number of inpatient and outpatient days during which the patient received daptomycin therapy, even if these were non-consecutive.
There were no restrictions on concomitant treatment in the EU-CORE study. The safety population comprised all eligible patients who had any safety parameters assessed, and the efficacy population comprised all eligible patients for whom clinical outcome was assessed. Safety was assessed for up to 30 days after the end of daptomycin treatment.
All reported deaths, adverse events (AEs) and serious AEs (SAEs), regardless of their relationship to daptomycin, were recorded, and the severity of AEs was determined. 
Statistical Analysis
Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). 
RESULTS

Patient Demographic and Clinical
Characteristics
Of the 6075 patients (5467 from Europe, 409
from Latin America and 199 from Asia) enrolled in the EU-CORE study, 472 (7.8%) patients had enterococcal infections as the primary diagnosis. All were included in both the safety and efficacy populations ( Table 1) .
Patients were predominantly adults with a median age of 65 (range 1-94) years and a median body weight of 75 (range 6-177) kg. The majority were male (63.3%) and Caucasian (87.7%; 
Daptomycin Prescribing Patterns
The most commonly prescribed dose of daptomycin was 6 mg/kg/day (47.0%), and 20.1% of patients received [6 mg/kg/day ( (Fig. 3) . Displaying the expected Gaussian distribution curve, the data showed only small proportions of E. faecalis and E. faecium isolates with daptomycin MICs = 4 mg/L (1.9% and 4%, respectively) or C8 mg/L (1.3% and 0.8%, respectively). Among these E. faecalis and E. faecium isolates, the VRE rate was 0.8% and 36.2%, respectively. Using the current CLSI susceptibility breakpoint for daptomycin (B4 mg/L), resistance rates of 1.3% for E. faecalis and 0.8% for E. faecium need to be considered. Table 5 . Most AEs and SAEs were considered as unrelated to daptomycin treatment by the investigator, with 11 (2.3%) and 3 (0.6%) treatment-related AEs and SAEs, respectively, being recorded. A total of 46 (9.7%) patients died during the study or follow-up (Table 5 ).
The main causes of death were multi-organ failure, sepsis and septic shock. Discontinuation of daptomycin treatment due to an AE occurred in 6.1% of patients. There were a total of five patients with rhabdomyolysis AEs and SAEs, of whom three were considered by the investigator as possibly treatment related (two AEs and one SAE). Of the patients with treatment-related rhabdomyolysis, two discontinued the study. 
DISCUSSION
The EU-CORE study illustrates real-world usage of daptomycin in the treatment of enterococcal infections. The many multinational sites enrolled in the EU-CORE study allowed a wide spectrum of patients. Overall, treatment of enterococcal infections with daptomycin was associated with high rates of clinical success. Daptomycin showed good effectiveness whether used as first-or second-line therapy. Available interventions for VRE are mostly based on expert opinion recommendations [25] .
A recent meta-analysis has showed that the two most commonly prescribed drugs, daptomycin and linezolid, were equally efficacious in blood stream infections due to VRE [26] . A 2-year retrospective study conducted at the Detroit Medical Center also showed that daptomycin was as efficacious as linezolid and b-lactams in Fig. 3 Daptomycin susceptibility of enterococci-Leipzig University Hospital, Germany, January to December 2014 Blood creatine phosphokinase increased 5 (1.1)
treating bacteremia due to VRE [27] . However, prolonged linezolid treatment has been associated with multiple safety concerns [28, 29] .
Daptomycin has previously been shown to be active against Enterococcus species with vancomycin non-susceptible E. faecalis and E. faecium being 100.0% and 99.8% susceptible to daptomycin, respectively [30] 
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